All the news Showing 10 of 81 articles from: TreatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year Liz Highleyman / 08 January 2019 Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ... Hepatitis B capsid assembly modulators show good antiviral activity Liz Highleyman / 21 December 2018 Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ... New simplified scoring system identifies people with hepatitis B in need of treatment in Africa Keith Alcorn / 02 July 2018 Liver enzyme and hepatitis B 'e' antigen test results are sufficient to determine which people with hepatitis B need antiviral treatment for the infection in sub-Saharan Africa, a study carried ... Switching to TAF improves safety in people with hepatitis B with kidney and bone risk factors Liz Highleyman / 04 May 2018 People with risk factors for tenofovir toxicity who switched from tenofovir disoproxil fumarate (TDF; Viread) to the new tenofovir alafenamide (TAF; Vemlidy) maintained hepatitis B virus (HBV) suppression and showed evidence of improved kidney and ... Hepatitis B capsid inhibitors look promising in early studies Liz Highleyman / 18 April 2018 Two experimental drugs that interfere with assembly of the hepatitis B virus (HBV) capsid and prevent production of functional new virus demonstrated good safety and promising antiviral activity in early clinical trials, according ... Tenofovir DF does not reduce the risk of mother-to-child hepatitis B transmission Liz Highleyman / 14 March 2018 Mothers who took tenofovir disoproxil fumarate (Viread) during pregnancy did not have a significantly lower risk of transmitting hepatitis B virus (HBV) to their infants compared with those who used ... Treatment that interferes with viral assembly shows promise for hepatitis B Liz Highleyman / 18 December 2017 JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in ... RNA interference therapy lowers viral biomarker in people with hepatitis B Liz Highleyman / 14 December 2017 ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the ... Immune modulator inarigivir looks promising for people with hepatitis B Liz Highleyman / 12 December 2017 Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA and antigens, and potency was ... ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive